CoraLite® Plus 488-conjugated EIF5A2 Monoclonal antibody
EIF5A2 Monoclonal Antibody for IF/ICC, FC (Intra)
Host / Isotype
Mouse / IgG1
Reactivity
human, rat
Applications
IF/ICC, FC (Intra)
Conjugate
CoraLite® Plus 488 Fluorescent Dye
CloneNo.
1F9B2
Cat no : CL488-67907
Synonyms
Validation Data Gallery
Tested Applications
Positive IF/ICC detected in | HepG2 cells |
Positive FC (Intra) detected in | HepG2 cells |
Recommended dilution
Application | Dilution |
---|---|
Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
Flow Cytometry (FC) (INTRA) | FC (INTRA) : 0.40 ug per 10^6 cells in a 100 µl suspension |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Product Information
CL488-67907 targets EIF5A2 in IF/ICC, FC (Intra) applications and shows reactivity with human, rat samples.
Tested Reactivity | human, rat |
Host / Isotype | Mouse / IgG1 |
Class | Monoclonal |
Type | Antibody |
Immunogen | EIF5A2 fusion protein Ag10852 相同性解析による交差性が予測される生物種 |
Full Name | eukaryotic translation initiation factor 5A2 |
Calculated molecular weight | 153 aa, 17 kDa |
Observed molecular weight | 20 kDa |
GenBank accession number | BC036072 |
Gene symbol | EIF5A2 |
Gene ID (NCBI) | 56648 |
RRID | AB_2934587 |
Conjugate | CoraLite® Plus 488 Fluorescent Dye |
Excitation/Emission maxima wavelengths | 493 nm / 522 nm |
Form | Liquid |
Purification Method | Protein G purification |
Storage Buffer | PBS with 50% Glycerol, 0.05% Proclin300, 0.5% BSA, pH 7.3. |
Storage Conditions | Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
Eukaryotic translation initiation factor 5A (EIF5A), a conserved lysine to hypusine, is strictly indispensable for the survival of eukaryotic cells. There are two EIF5A isoforms in humans: EIF5A1 and EIF5A2. EIF5A2 has been reported to be overexpressed in gallbladder cancer, upper urinary tract urothelial carcinoma, gastric cancer, prostate cancer, nasopharyngeal carcinoma, and cervical cancer. EIF5A2 upregulation in cancer tissues is associated with poor prognosis in these patients.
Protocols
Product Specific Protocols | |
---|---|
IF protocol for CL Plus 488 EIF5A2 antibody CL488-67907 | Download protocol |
FC protocol for CL Plus 488 EIF5A2 antibody CL488-67907 | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |